Company Filing History:
Years Active: 2004
Title: Conceicao Minetti: Innovator in Vaccine Development
Introduction
Conceicao Minetti is a prominent inventor based in Silver Spring, MD (US). She has made significant contributions to the field of immunology, particularly in the development of vaccines. Her innovative work focuses on enhancing the safety and efficacy of vaccine compositions.
Latest Patents
Minetti holds a patent for "Modified immunogenic pneumolysin compositions as vaccines." This invention relates to modified pneumolysin polypeptides that retain the immunogenic nature of pneumolysin but have reduced or undetectable hemolytic activity compared to native pneumolysin. The invention also provides a method for generating novel pneumolysin variants with these desired characteristic properties. Additionally, it offers immunogenic compositions useful as pharmaceutical compositions, including vaccines, in which non-toxic, modified pneumolysin is used to stimulate protective immunity. The vaccines may consist of compositions in which the modified pneumolysin is conjugated to bacterial polysaccharides or may be carried on an attenuated viral vector. Furthermore, the invention provides a method of using the non-toxic, modified pneumolysin toxoid to stimulate antibodies in a treated individual, which can then be isolated and transferred to a second individual, thereby conferring protection.
Career Highlights
Minetti is associated with Baxter International Inc., a leading company in the healthcare sector. Her work at Baxter has allowed her to focus on innovative solutions in vaccine development, contributing to advancements in public health.
Collaborations
Minetti has collaborated with notable colleagues, including Francis Michon and Jeffrey K Pullen. These collaborations have further enriched her research and development efforts in the field of immunology.
Conclusion
Conceicao Minetti's contributions to vaccine development through her innovative patent work exemplify her commitment to enhancing public health. Her research continues to pave the way for safer and more effective immunogenic compositions.